Abstract
Apixaban is a new oral anticoagulant (NOACs: Novel Oral Anticoagulant), like dabigatran, rivaroxaban, and edoxaban. All of them are prescribed to patients with non valvular atrial fibrillation or venous thromboembolism, to replace warfarin, because of the lower probability of bleeding, however they can cause bleeding by themselves. Bleeding is an adverse event in patients taking anticoagulants. It is associated with a significant increase of morbidity and risk of death. However, these drugs should be used only for the time when anticoagulation is strictly required, especially when used for preventing deep vein thrombosis. Prolonged use increases the risk of bleeding. In the ARISTOTLE Trial Apixaban, compared with warfarin, was associated with a lower rate of intracranial hemorrhages and less adverse consequences following extracranial hemorrhage. Many physicians still have limited experience with new oral anticoagulants and about bleeding risk managment. We reviewed the available literature on extracranial and intracranial bleeding concerning apixaban.
Keywords: Apixaban, extracranial, intracranial bleeding, anticoagulant, thrombosis, artial fibrillation.
Current Drug Targets
Title:To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban
Volume: 19 Issue: 6
Author(s): Marco Matteo Ciccone*, Annapaola Zito, Fiorella Devito, Maria Maiello and Pasquale Palmiero
Affiliation:
- Cardiovascular Diseases Section, Department of Emergency and Organ Transplantation (DETO), University of Bari,Italy
Keywords: Apixaban, extracranial, intracranial bleeding, anticoagulant, thrombosis, artial fibrillation.
Abstract: Apixaban is a new oral anticoagulant (NOACs: Novel Oral Anticoagulant), like dabigatran, rivaroxaban, and edoxaban. All of them are prescribed to patients with non valvular atrial fibrillation or venous thromboembolism, to replace warfarin, because of the lower probability of bleeding, however they can cause bleeding by themselves. Bleeding is an adverse event in patients taking anticoagulants. It is associated with a significant increase of morbidity and risk of death. However, these drugs should be used only for the time when anticoagulation is strictly required, especially when used for preventing deep vein thrombosis. Prolonged use increases the risk of bleeding. In the ARISTOTLE Trial Apixaban, compared with warfarin, was associated with a lower rate of intracranial hemorrhages and less adverse consequences following extracranial hemorrhage. Many physicians still have limited experience with new oral anticoagulants and about bleeding risk managment. We reviewed the available literature on extracranial and intracranial bleeding concerning apixaban.
Export Options
About this article
Cite this article as:
Ciccone Matteo Marco*, Zito Annapaola, Devito Fiorella, Maiello Maria and Palmiero Pasquale, To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban, Current Drug Targets 2018; 19 (6) . https://dx.doi.org/10.2174/1389450116666151001113932
DOI https://dx.doi.org/10.2174/1389450116666151001113932 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Naturally Occurring Calanolides: An Update on Their Anti-HIV Potential and Total Syntheses
Recent Patents on Biotechnology Cardiac Gene Therapy: Therapeutic Potential and Current Progress
Current Gene Therapy Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy
Current Pharmaceutical Design Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Ubiquitin-Protein Ligases - Novel Therapeutic Targets?
Current Protein & Peptide Science The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery The Paradox of Caffeine-Zolpidem Interaction: A Network Analysis
Current Drug Targets A Mechanistic Overview on Male Infertility and Germ Cell Cancers
Current Pharmaceutical Design Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Development of Anti-Viral Agents Using Molecular Modeling and Virtual Screening Techniques
Infectious Disorders - Drug Targets The Role of Reactive Species in Epileptogenesis and Influence of Antiepileptic Drug Therapy on Oxidative Stress
Current Neuropharmacology Molecularly Targeted Therapy in Breast Cancer: The New Generation
Recent Patents on Anti-Cancer Drug Discovery Interstitial Lung Disease in Systemic Lupus Erythematosus, Sjogren’s Syndrome, and Mixed Connective Tissue Disease
Current Respiratory Medicine Reviews CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Cigarette Smoking and Hypertension
Current Pharmaceutical Design Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
Current Signal Transduction Therapy Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging